Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzymes product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner.
View all »
Recent Releases
May 9, 2013
Tranzyme Pharma Announces First Quarter 2013 Financial Results
May 2, 2013
Tranzyme Pharma to Report First Quarter 2013 Financial Results










